Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current Status of Immunological Adjuvants

Current Status of Immunological Adjuvants Sixty years ago Ramon demonstrated that it was possible to augment the antitoxin response to diphtheria and tetanus by administering vaccines with pyogenic bacteria or with various additional compounds (1). Since that time, clinicians and immunologists have sought to potentiate the immune response with adjuvants while attempting to minimize the often present side effects. An explosion of information concerning the complexity and sophisti­ cation of immune regulation has occurred in the past decade. Coupled with presently available biosynthetic and recombinant DNA technology, this knowledge is permitting development of vaccines possessing antigenic epitopes that were previously impossible to produce. Current vaccine candidates, for example, include synthetic peptides mimicking streptococ­ cal (2), gonococcal (3), and malarial antigens (4). However, these purified antigens are generally weak immunogens that will require adjuvants to evoke protective immunity. Thus, a corresponding surge of interest has arisen in the development of potent nontoxic adjuvants that will enhance the immunogenicity of haptenic epitopes. An adjuvant may also be needed for conventional vaccines in order to elicit an earlier, more potent, or more 369 0732-0582/86/0410-0369$02.00 WARRE N, VOGEL & CHEDID prolonged response, or in cases where antigen supply is limited or too costly to produce. The development http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Immunology Annual Reviews

Current Status of Immunological Adjuvants

Download PDF
20 pages

Loading next page...
 
/lp/annual-reviews/current-status-of-immunological-adjuvants-8pqYUhTNok

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Annual Reviews
Copyright
Copyright 1986 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0732-0582
eISSN
1545-3278
DOI
10.1146/annurev.iy.04.040186.002101
pmid
2871847
Publisher site
See Article on Publisher Site

Abstract

Sixty years ago Ramon demonstrated that it was possible to augment the antitoxin response to diphtheria and tetanus by administering vaccines with pyogenic bacteria or with various additional compounds (1). Since that time, clinicians and immunologists have sought to potentiate the immune response with adjuvants while attempting to minimize the often present side effects. An explosion of information concerning the complexity and sophisti­ cation of immune regulation has occurred in the past decade. Coupled with presently available biosynthetic and recombinant DNA technology, this knowledge is permitting development of vaccines possessing antigenic epitopes that were previously impossible to produce. Current vaccine candidates, for example, include synthetic peptides mimicking streptococ­ cal (2), gonococcal (3), and malarial antigens (4). However, these purified antigens are generally weak immunogens that will require adjuvants to evoke protective immunity. Thus, a corresponding surge of interest has arisen in the development of potent nontoxic adjuvants that will enhance the immunogenicity of haptenic epitopes. An adjuvant may also be needed for conventional vaccines in order to elicit an earlier, more potent, or more 369 0732-0582/86/0410-0369$02.00 WARRE N, VOGEL & CHEDID prolonged response, or in cases where antigen supply is limited or too costly to produce. The development

Journal

Annual Review of Immunology – Annual Reviews

Published: Apr 1, 1986

There are no references for this article.